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Abstract
We describe here two novel endogenous variants of the human endoplasmic reticulum (ER) cargo receptor SEL1LA,
designated p38 and p28. Biochemical and RNA interference studies in tumorigenic and non-tumorigenic cells indicate that
p38 and p28 are N-terminal, ER-anchorless and more stable relative to the canonical transmembrane SEL1LA. P38 is
expressed and constitutively secreted, with increase after ER stress, in the KMS11 myeloma line and in the breast cancer
lines MCF7 and SKBr3, but not in the non-tumorigenic breast epithelial MCF10A line. P28 is detected only in the poorly
differentiated SKBr3 cell line, where it is secreted after ER stress. Consistently with the presence of p38 and p28 in culture
media, morphological studies of SKBr3 and KMS11 cells detect N-terminal SEL1L immunolabeling in secretory/degradative
compartments and extracellularly-released membrane vesicles. Our findings suggest that the two new SEL1L variants are
engaged in endosomal trafficking and secretion via vesicles, which could contribute to relieve ER stress in tumorigenic cells.
P38 and p28 could therefore be relevant as diagnostic markers and/or therapeutic targets in cancer.
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Introduction
Multiple homeostatic mechanisms that control protein folding
and assembly and promote the disposal of defective proteins
operate in distinct cellular compartments to afford protection from
endogenous proteotoxic stress [1–4]. The endoplasmic reticulum
(ER) is the folding and assembly site for resident structural proteins
and enzymes, as well as for secretory and plasma membrane
proteins [5]. This remarkable workload is managed by efficient
and high-fidelity protein folding and misfold-correction systems,
based on ATP-dependent chaperones and disulfide isomerases, in
parallel with quality control mechanisms that allow Golgi transit
only to properly folded proteins [6]. Furthermore, clearance of
aberrant proteins retained in the ER is mediated through the ER-
associated degradation (ERAD) pathway [7], a multi-step process
which requires recognition of defective proteins, retro-transloca-
tion to the cytosolic side of the ER membrane, ubiquitination and
degradation by the 26S proteasome [8].
Nonetheless, the cellular protein-folding capacity and the
ERAD pathway may be impaired and/or overloaded by a variety
of pathological conditions that perturb energy and calcium
homeostasis, increase secretory protein synthesis and/or interfere
with protein glycosylation and disulfide bond formation [6,9]. In
such cases the intralumenal accumulation of unfolded/malfolded
proteins determines ER stress, which in turn activates a complex
cascade of survival signaling pathways, collectively termed
unfolded protein response (UPR). This aims at relieving ER stress
by attenuating the rate of protein synthesis and by up-regulating
the protein folding enzymes, the ERAD machinery and the
secretory capacity [6,10,11]. If homeostasis cannot be restored,
UPR-activated machineries can trigger death/senescence pro-
grams [12].
It is increasingly evident that the UPR has a major role in
cancer, where it is required to maintain the malignant phenotype
and to develop resistance to chemotherapy [13]. In fact cancer
cells must adapt to nutrient starvation and hypoxia, which affect
cellular redox status and availability of energy from ATP
hydrolysis. This is expected to compromise their protein folding
capacities, predisposing to ER stress [14–16]. Hence, up-
regulation of the ERAD-UPR pathways may substantially
contribute to the complex cellular adaptations needed for cancer
progression [17,18]. In this regard it is known that many ER-
resident proteins are deregulated, post-translationally modified,
abnormally secreted and/or cell surface re-localized in various
cancer types [13,19–21].
The multifaceted ERAD gene SEL1L (sel-1 suppressor of lin-12,
C.elegans-like) encodes for at least three different protein isoforms,
i.e., the canonical ER-resident SEL1LA, a cargo receptor that
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the smaller, recently cloned SEL1LB and -C, that lack the C-
terminal SEL1LA membrane-spanning region for insertion into
the ER [26]. Several reports have demonstrated that SEL1L
protein expression varies in human tumors relative to matched
normal tissues, suggesting an involvement in cancer progression
[27–32].
We report here the identification, characterization and
subcellular localizations of two novel anchorless endogenous
SEL1L variants, p38 and p28, studied in the breast cancer cell
lines SKBr3 and MCF7, the multiple myeloma line KMS11 and
the non-tumorigenic lines MCF10A (breast) and 293FT (embryo
kidney). We found that: i. p38 and p28 are encoded by the 59 end
of the SEL1L gene; ii. p38 is up-regulated and constitutively
secreted in the cancer cells, differently from the non-tumorigenic
MCF10A line; iii. p28 is expressed only in the poorly differentiated
SKBr3 breast cancer line; iv. ER stress/UPR strongly enhance p38
secretion in the cancer cells; v. N-terminal SEL1L is present in
secretory and degradative compartments of SKBr3 and KMS11
cells, and in vesicles released into the extracellular space. Overall,
the biochemical and morphological evidence supports the view
that SEL1L p38 and p28 are implicated in pathways linking ER
stress/UPR to endosomal trafficking and to secretion via
extracellularly-shed vesicles. Furthermore the expression of p38
and p28 and their release into the culture medium is upregulated
in tumorigenic relatively to non-tumorigenic cells, suggesting
cancer-related functions.
Materials and Methods
Cell lines, culture conditions, transfections
Human multiple myeloma KMS11, breast cancer MCF7,
SKBr3, MDAMB453, lymphoma Namalwa, cervical cancer HeLa
and glioblastoma G144, G166, and G179 cells were maintained in
RPMI containing 10% fetal bovine serum (Euroclone, Celbio,
Pero, Italy). Human embryo 293 FT kidney cells were cultured in
DMEM containing 10% fetal bovine serum (Euroclone, Celbio,
Pero, Italy). Non-tumorigenic breast MCF10A cells [33] were
maintained in MEBM (Lonza, Treviglio, Italy), supplemented with
EGF, 20 ng/ml; bFGF, 20 ng/ml; insulin, 10 mg/ml; and
hydrocortisone, 0.5 mg/ml. Non-tumorigenic human fetal brain
CB660 cells, obtained from Prof. Austin Smith (Cambridge, UK),
were maintained in human neural stem cell medium on laminin-
coated dishes. Cells were transiently transfected with the indicated
plasmids and siRNAs by Lipofectamine 2000 (Invitrogen,
S.Giuliano M.se, Italy) and harvested after the indicated time.
Cells were treated with DTT (2 mM) for 3 hrs, MG132 (10 mM)
for 3 or 22 hrs, cycloheximide (200 mg/ml) for 3, 6, 18 hrs, as
indicated.
Constructs
Tagged TPD52 isoform 1 constructs were generated by cloning
the full-length TPD52 isoform 1 coding sequence, fused with a
myc or GFP tag at the 39 end, into pCDNA3.1myc-Hys(-)A or
peGFPN3 vectors, respectively (Invitrogen, S. Giuliano M.se,
Italy). The Myc-tagged SEL1LB constructs were previously
described [26].
RT-PCR
Total RNA was extracted using the TRI Reagent solution
(Applied Biosystems, Monza Italy). RNA was reverse-transcribed
with SuperScript TM II Reverse Transcriptase (Invitrogen, S.
Giuliano M.se, Italy) according to manufacturer’s instructions.
Semi-quantitative PCR amplifications were performed with 2 mlo f
RT product per reaction and 0.15 units of Platinum Taq DNA
Polymerase High Fidelity (Invitrogen, S. Giuliano M.se, Italy),
using a Mastercycler instrument (Eppendorf, Milan, Italy). PCR
conditions for all the experiments here described were: denatur-
ation at 95uC for 3 min, followed by 22 cycles at 95uC for 30
seconds, then at 60uC for 72 seconds. The following specific
primers were used:
SEL1LA: sense: 59-ctcgctaacaggaggctcagtagtac-39; antisense: 59-
gccactggcatgcatctgagc-39
HRD1: sense: 59-ggccagggcaatgttccgc-39; antisense: 59-
gtccattgcctggagctcc-39.
BIP: sense: 59-tgcagcaggacatcaagttc-39; antisense: 59-
cgctggtcaaagtcttctcc-39
ATF6: sense: 59-ctgatggctgttcaatacac-39; antisense: 59-aatgact
cagggatggtgct-39
CHOP: sense: 59-gatggcagctgagtcattgc-39; antisense: 59-
atgcttggtgcagattcacc-39
XBP-1: sense: 59-ccttgtagttgagaaccagg-3; antisense: 59-
ggggcttggtatatatgtgg-39
GADD45b: sense: 59-ggaagagctcgtggcgtgcg-39; antisense: 59-
gtctcgggcctcggtggtgc-39
SEL1LB: sense: 59-ccggccccgagaggaggatgcgggtc-39; antisense:
59-ggggaaacatagataccatg-39
SEL1LC: sense: 59-ccggccccgagaggaggatgcgggtc-39; antisense:
59-ggggcaatcagccaaactaatca-39
HPRT: sense: 59-aattatggacaggactgaacgtc-39 antisense: 59-
cgtggggtccttttcaccagcaag-39
Western blotting, immunoprecipitation, analysis of
culture supernatants, N-glycosidase F and
endoglycosidase H digestion
Monoclonal SEL1L antibody was raised against the N-terminal
peptide of human SEL1L [34]. Affinity-purified polyclonal
antibody to the SEL1L N-terminus was kindly provided by Dr.
H.L. Ploegh [35]. Affinity-purified polyclonal C-terminal SEL1L
antibody was raised against a bacterially-expressed recombinant
fragment encoding amino acids 575–738 of human SEL1L
(Primm, Milan, Italy). Monoclonal anti-vinculin and anti-myc
antibodies were purchased from Sigma-Aldrich (Sigma-Aldrich,
Milan, Italy). Polyclonal anti-TPD52 was kindly provided by Prof.
J. Byrne (University of Sydney, Sydney, NSW, Australia). Cells
were lysed in 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1%
NP40, containing protease inhibitors (Pierce, Celbio, Pero, Italy).
Protein concentrations were determined by the Bradford assay;
samples were resolved on SDS-polyacrylamide gels, blotted onto
PVDF membranes, probed with specific antibodies and developed
with ECL (Genespin, Milan, Italy). For immunoprecipitation cell
lysates were pre-cleared and incubated with antibodies immobi-
lized on protein G-sepharose (Invitrogen S. Giuliano M.se, Italy).
Immunoprecipitates were washed twice with 10 mM Tris-HCl
pH 7.4, 150 mM NaCl, 0,25% NP40, once with 5 mM Tris-HCl,
and eluted with sample buffer before gel electrophoresis. For
analysis of supernatants cells were washed and incubated with
OPTIMEM (Invitrogen, S. Giuliano M.se, Italy) for 16 hrs.
Supernatants were recovered, centrifuged, precipitated with 10%
TCA, re-suspended with 1 M Tris-HCl pH 7.4 and resolved on
SDS polyacrylamide gels. All Western blots were performed using
the X-BLOT Chamber (www.isenet.it).
For digestion by N-glycosidase F (PNGase F) or endoglycosidase
H (endo H), cell lysates were denatured by heating at 95uCi n
0.05% SDS, 0.1% mercaptoethanol for 10 min and then
incubated at 37uC for 1 h with or without PNGase F or endo H
(New England Biolabs, Celbio, Pero, Italy), according to the
supplier’s indications.
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SKBr3 cells, grown on coverslips, untreated or treated with
DTT as described above, were fixed with 4% paraformaldehyde in
PBS for 30 min, washed in 0.1 M glycine for 20 min, and
permeabilized in 0.1% Triton X-100 for additional 5 min. To
investigate the subcellular localizations of SEL1L, the cells were
incubated with the N-terminal anti-SEL1L monoclonal antibody
[34] and with polyclonal antibodies against the ER marker
calreticulin (Affinity Bioreagents, Breda, The Netherlands) and the
Golgi marker giantin (Covance, Princeton, NJ, USA). The nuclei
were stained with 4,6-diamido-2-phenylindole (DAPI, Sigma-
Aldrich, Milan, Italy). Primary antibodies were visualized using
fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Cap-
pel Research Products) or Texas-Red-conjugated goat anti-rabbit
IgG (Jackson Immunoresearch Laboratories) for 30 min at room
temperature. Cells were analyzed using an Apotome Axio
Observer Z1 inverted microscope (Zeiss, Oberkochen, Germany),
equipped with an AxioCam MRM Rev.3 at 40X magnification.
Colocalization of fluorescence signals was analyzed with AxioVi-
sion 4.6.3 software. Image analysis was performed using Adobe
Photoshop.
Cryoimmunoelectron microscopy
Cells processed for cryoimmunoelectron microscopy were
grown as above and fixed in 2% paraformaldehyde, 0.2%
glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, for 2 hrs at
25uC. Cells were scraped off the coverslips, centrifuged, embedded
into 10% gelatin (Sigma-Aldrich) in 0.1 M PBS, pH 7.4 and
solidified on ice. After infusion in 2.3 M sucrose overnight at 4uC,
cell blocks were mounted on aluminum pins and frozen in liquid
nitrogen. Ultrathin cryosections (60 nm) were cut at 2120uC
using an Ultracut EM FC6 cryoultramicrotome (Leica Micro-
systems, Vienna, Austria), collected with 1% methylcellulose in
1.15 M sucrose and single- or double-immunolabelled with
primary antibodies. Bound antibodies were visualized using goat
anti-mouse conjugated with 5- or 15-nm colloidal gold (British
BioCell International, Cardiff, UK) or by protein-A conjugated
with 10-nm colloidal gold (supplied from G.Posthuma and J. Slot,
Utrecht, The Netherlands). Immunolabeling was performed with
the following primary antibodies: monoclonal anti-SEL1L N-
terminus [34], polyclonal anti-SEL1L N-terminus [35], polyclonal
anti SEL1L-C terminus, polyclonal anti-calreticulin (Affinity
Bioreagents), anti-CD63 monoclonal H5C6, developed by J.T.
August and J.E.K. Hildreth, obtained from the Developmental
Studies Hybridoma Bank developed under the auspices of the
NICHD and maintained by The University of Iowa, Dept. of
Biology (Iowa City, IA 52242), and monoclonal anti-c-Myc
(Sigma-Aldrich) for SEL1LBmyc-transfected 293 FT cells [26].
Single and double immunolabeling were performed as described
previously [23,36]. Cryosections were analyzed with a Philips
CM10 transmission electron microscope.
Off-gel proteins fractionation
Semi-liquid phase isoelectrofocusing fractionation was per-
formed on an Off-Gel 3100 apparatus (Agilent Technologies,
Cernusco, IT) using a 24 cm strip with immobilized pH gradient
gels in the 4–7 range. Total cell lysate samples (360 ml,
corresponding to 1300 mg of proteins) were mixed with 3240 ml
of isoelectric focusing buffer (Agilent Technologies) and loaded
onto the apparatus. Protein fractionation was performed for 26 hrs
with maximum 8000 Volt for a total of 60,000 V/hrs, according
to the manufacturer’s protocol. The resulting liquid fractions
(150 ml) with 0.25 pH range were collected and aliquots of proteins
further resolved on 10% acrylamide SDS-PAGE for Western blot
probing.
Protein identification by MALDI-TOF mass spectrometry
(MS) analysis
Bands of interest from SDS-PAGE were excised from gels,
reduced, alkylated and digested overnight with bovine trypsin
(Roche, Milan, Italy), as previously described [37]. One ml( 1ml)
aliquots of the supernatant were used for mass analysis using the
dried droplet technique and a-cyano-4-hydroxycinnamic acid as
matrix. Mass spectra were obtained on a MALDI–TOF Voyager-
DE STR mass spectrometer (Applied Biosystem, Foster City, CA).
Alternatively, acidic and basic peptide extraction from gel pieces
after tryptic digestion was performed and the resulting peptide
mixtures subjected to a single desalting/concentration step before
MS analysis over Zip-TipC18 (Millipore Corporation, Bedford,
MA,USA).Spectrawereinternallycalibratedusingtrypsinautolysis
products and processed via Data Explorer software. Proteins were
unambiguously identified by searching a comprehensive non-
redundant protein database of the National Center for Biotechnol-
ogy Information (NCBI, http://www.ncbi.nlm.nih.gov/) and the
Mass Spectrometry protein sequence DataBase (MSDB, http://
msdn.microsoft.com/en-us/library/ms187112.aspx), selected by
default using in house the software programs ProFound v4.10.5
and Mascot v1.9.00, respectively [38,39]. One missed cleavage per
peptide was allowed, and an initial mass tolerance of 50 ppm was
used in all searches.
Results
Novel ER-anchorless SEL1L variants
A monoclonal antibody raised against the N-terminus of the
SEL1L protein [34] was used to screen a panel of whole lysates
from five human cell lines, including MCF7 and SKBr3 (breast
cancer), KMS11 (Ig-K-secreting multiple myeloma), 293FT
(embryo kidney) and the non-tumorigenic epithelial breast cell
line MCF10A. Besides the well-known 95 KDa SEL1LA protein,
two additive bands, designated as p38 and p28, were visualized at
approximately 38 KDa and 28 KDa (Figure 1A). While p28 was
exclusively detected in the SKBr3 line, p38 was strongly expressed,
at levels higher than SEL1LA, in all the cancer cell lines tested,
with lower levels in MCF10A, where SEL1LA expression (protein
and RNA) was also lower (Figure 1A–B). A polyclonal antibody
raised against the SEL1L C-terminus, which encompasses the
SEL1LA tail anchor for insertion into the ER membrane, detected
the 95 KDa SEL1LA protein, but not p38 and p28, although an
additional band was evidenced at about 55 KDa, which could
indicate the carboxy-terminal fragment resulting from cleavage of
the native protein (Figure S1A). Notably the p38 variant was
strongly expressed also in other tested cancer cell lines, including
Namalwa (lymphoma), MDAMB453 (breast cancer), HeLa
(cervical cancer), and G144, G166, G179 (glioblastoma), all of
which resulted negative for p28 (Figure S1B). Analysis of SEL1L
protein profile in the non-tumorigenic human fetal brain cell line
CB660 compared to the three glioblastoma cell lines (Figure S1B)
provided further in vitro evidence that p38 was indeed expressed at
higher levels in tumor cells.
When analyzed in 293FT cells by SDS-PAGE and immunoblot
under reducing condition, p38 migrated as a monomer, while it
appeared as a doublet under non-reducing conditions (Figure 1C).
Thus, while many proteins containing intramolecular disulphide
bonds migrate more rapidly under non-reducing conditions due to
the more compact native structure [40], p38 migrated faster in
reduced than in oxidized state, a phenomenon suggesting that the
Novel SEL1L Variants
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disulphide bonds [41–43]. The p28 signal appeared as a single
band under both reducing and non-reducing conditions (data not
shown).
To ascertain that p38 and p28 were bonafide endogenous SEL1L-
encoded proteins, SKBr3 and 293FT cells were transfected with
siRNAs targeting the SEL1L N-terminus. The levels of the three
SEL1L signals were significantly lower in the cells treated with
Figure 1. p38 and p28 are related SEL1L variants. A. Western blot analysis: Lysates (50 ug) from different cell lines, including 293FT (embryo
kidney), MCF10A (non-tumorigenic breast), MCF7, SKBr3 (breast cancer) and KMS11 (multiple myeloma), were resolved by SDS-PAGE (10%) and
probed with monoclonal to SEL1L N-terminus. Vinculin was used as a loading control. In addition to SEL1LA (95 KDa), the N-terminal SEL1L antibody
recognized two smaller encoded products, at approximately 38 and 28 KDa (designated p38 and p28). P38 was more abundant than SEL1LA and
both were up-modulated in the cancer cell lines relative to MCF10A. P28 was detectable only in SKBr3. Bands above p38, probably corresponding to
immature precursors or post-translationally modified products, were occasionally seen in the tested cell lines. The blot is representative of four
independent experiments. B. RT-PCR analysis: RNAs from KMS11, MCF10A and SKBr3 cells were analyzed by RT-PCR using primers specific for SEL1LA.
Signals shown were obtained with 27 cycles for SEL1LA. HPRT was used as a loading control. SEL1LA was up-modulated in the cancer cell lines relative
to the non-tumorigenic MCF10A line. The image is representative of three different assays based on independent treatments. C. Intra/inter-molecular
disulfide bonds analysis of p38. 293FT cell lysates were resolved by SDS-PAGE (10%) under reducing (R) and non-reducing (NR) conditions and blotted
with monoclonal anti-SEL1L N-terminus. P38 migrated as a doublet under non-reducing conditions (the lanes comparing p38 migration under
reducing and non-reducing conditions are from the same gel). D. Down-modulation of SEL1LA, p28 and p38 by SEL1L small interfering RNA (siRNA):
Left panel: SKBr3 cells (3610
5) were treated with scrambled siRNA or siRNA specific to SEL1L (siRNA SEL1L) for 48 hrs, followed by a second siRNA
treatment for further 48 hrs. Silencing efficiency was verified by Western blot. SEL1LA, p28 and p38 protein levels decreased close to 55%, 30% and
16% respectively compared to cells treated with scrambled siRNA. Vinculin was used as a loading control. Right panel: 293FT cells (6610
5) were
treated with scrambled siRNA or siRNA-SEL1L for 48 hrs. SEL1LA and p38 protein levels decreased close to 45% and 23% respectively compared to
cells treated with scrambled siRNA. Vinculin was used as a loading control. The histograms show values normalized relative to housekeeping signals
and expressed as fold modulation relative to controls, densitometric analysis was determined using the Scion imaging program. (www.scioncorp.
com). The data are the averages of three independent experiments, 6SD; Student’s t-test was used to determine statistical significance *p,0.1;
**p,0.05. E. Analysis of p38 and SEL1LA stability: 293 FT cells (6610
5) were treated for 3, 6 and 18 hours with cycloheximide (CHX, 200 mg/ml).
Aliquots of lysates (50 mg) were resolved by SDS-PAGE (10%) and probed with monoclonal anti-SEL1L and anti-vinculin antibodies. Unlike SEL1LA,
which progressively decreased during cycloheximide exposure up to about 90%, p38 levels did not change significantly. The histogram shows the
densitometric quantifications obtained through Scion imaging program (www.scioncorp.com). Values were normalized relative to housekeeping
signals and expressed as fold modulation relative to untreated samples. The data are averages of two independent experiments, 6SD.
doi:10.1371/journal.pone.0017206.g001
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for SEL1LA and of 16% and 23% for p38 in SKBr3 and 293FT
cells respectively, and of 30% for p28 in SKBr3 (Figure 1D). In
293FT cells, inhibition of protein synthesis by cycloheximide for 3
and 6 hrs, time windows which did not result in cell death,
decreased the SEL1LA level by about 50%, but had almost no
effect on p38 (Figure 1E). At 18 hrs, cycloheximide caused cell
death, concomitant to a drastic depletion of SEL1LA (about 90%),
but did not modify the p38 level. This indicates that p38 is more
stable than SEL1LA, which may account for the modest p38
depletion by siRNAs to the SEL1L N-terminus.
Altogether, these data indicate that p38 and p28 are SEL1L
protein variants encoded by the 59 end of the SEL1L gene. While
p38 resulted expressed in all the tested cell lines, with higher levels
in the cancer lines, p28 was detected only in the poorly
differentiated metastatic breast cancer line SKBr3 [44].
The p38 and p28 variants display secretory properties
To explore the behavior and secretion of p38 and p28 in cells
under ER stress/UPR, we analyzed by SDS-PAGE and
immunoblot cell lysates and culture supernatants of MCF10A,
SKBr3 and KMS11 cells under normal conditions and after
treatment with DTT, which causes protein misfolding by reducing
disulfide bonds [45] (Figure 2A–C). In all the tested cells DTT
triggered ER stress/UPR, assessed by XBP-1 splicing combined
with BIP, ATF6 and CHOP up-modulation, and boosted SEL1LA
mRNA expression (Figure 2A1,C1; Figure S2A–C), while the
SEL1LA protein level did not increase significantly (Figure 2A–C,
C2). P38, but not SEL1LA, was readily detectable in SKBr3 and
KMS11 supernatants, increasing close to three- and five-fold
respectively after DTT (Figure 2B–C). No evidence of p38 was
detected in MCF10A supernatants, under both normal and DTT-
stressed conditions (Figure 2A). P28 was exclusively found after
DTT treatment and only in the supernatant of the SKBr3 cell line,
which expresses this variant (Figure 2B).
MG132, which determines ER stress through ERAD blockage by
proteasome inhibition [46], was tested on the KMS11 myeloma line,
beingknownthat the breast cancer celllinesare quiteresistanttosuch
treatment [47]. An approximately fivefold increase of p38 in the
KMS11 medium occurred after three hours of MG132 exposure,
concomitant to a significant increase in CHOP and GADD45b
expression, indicative of ER stress/UPR activation, even if in absence
of XBP-1 splicing and BIP and ATF6 up-modulation (Figure 2C–C1;
Figure S2C). MG132 treatment also increased the SEL1LA protein
level (Figure 2C, C2), which is consistent with reported evidence that
SEL1LA is degraded via proteasome [22]. In contrast, the mRNA
levels of SEL1LA and of the E3 ubiquitin ligase HRD1 decreased,
suggesting that proteasomal blockage attenuated the transcription of
these ERAD genes, whose products associate in the ER membrane-
embedded HRD1-SEL1L ubiquitin ligase complex (Figure 2C1;
Figure S2C). Prolonged MG132 treatment (22 hours) resulted in cell
death, concomitant with up-modulation of BIP, CHOP and
GADD45b, indicative of UPR activation (Figure S2C).
Altogether these data indicate that p38 is constitutively secreted
in at least two different cancer cell models, i.e., breast cancer and
myeloma, and that secretion is up-regulated by ER stress/UPR.
This does not occur in the non-tumorigenic MCF10A breast line.
Secretion of p28 is restricted to the poorly differentiated breast
cancer cell line SKBr3, which expresses this variant, and occurs
only after ER stress/UPR.
Subcellular localizations of SEL1L products
To define the subcellular localizations of the endogenous
SEL1L products, SKBr3 and KMS11 cells labeled with the
monoclonal or polyclonal antibodies against SEL1L were analyzed
by high-resolution immunoelectron microscopy (IEM). Ultrathin
cryosections of untreated SKBr3 cells revealed that, in addition to
the ER, the monoclonal and polyclonal antibodies against the
SEL1L N-terminus [34,35] labeled peripheral cytoplasmic vesi-
cles, often associated with structures morphologically consistent
with late endosomes/multivesicular bodies (MVBs), organelles
containing membrane vesicles that can be released extracellularly
as exosomes [48] (Figure 3A, B). In agreement, immunofluores-
cence showed that the immunolabeling obtained with the
monoclonal antibody to the SEL1L N-terminus co-localized with
the ER marker calreticulin and, in few dots only, with the Golgi
marker giantin, but was uniquely present in the peripheral
cytoplasm (Figure 3D–I). Double immunolabeling by IEM
confirmed that SEL1L codistributed with calreticulin along the
ER, while only SEL1L was present in endosomes/MVBs (Figure
S3G). In DTT-treated SKBr3 cells the IEM labeling was more
evident along the plasma membrane (PM), particularly in
association with microvilli, and in 80–200 nm vesicles apparently
emerging from the PM and shed extracellularly (Figure 4A–A1, C,
F; Figure S3H–I), as observed for the exogenous myc-tagged
SEL1LB protein in SEL1LBmyc-transfected 293 FT cells (Figure
S3J–K) [26].
Immunolabeling with CD63, a marker of lysosomes/MVBs
[48], revealed that CD63 and SEL1L were similarly distributed
along the microvilli and in membrane vesicles released from the
PM (Figure 4D, G, I; Figure S3J), in addition to the localization in
lysosomes/MVBs (Figure 4B). Furthermore double immunolabel-
ing revealed that N-terminal SEL1L codistributed with CD63 in
some extracellular vesicles (Figure 4E, H; Figure S3K), while the
C-terminal SEL1L antibody, which recognizes only the full-length
SEL1LA protein, was detected in the ER (Figure 4J). In
agreement, immunofluorescence analysis evidenced that N-
terminal SEL1L was uniquely localized in peripheral dots and
along PM profiles (Figure S3A–F), which were not labeled with the
ER marker calreticulin.
Correspondingly, in MG132-treated KMS11 cells, IEM showed
that SEL1L was present in vesicles dispersed in the peripheral
cytoplasm or associated with late endosomes/MVBs (Figure 5A,
C). Furthermore, in areas where MVBs were adjacent to the PM,
SEL1L-labeled vesicles appeared to emerge into the extracellular
space (Figure 5B).
Overall the morphological data indicate that N-terminal SEL1L
localizes in endosomes/MVBs and in vesicles released into the
extracellular space, consistently with the SDS-PAGE and
immunoblot analysis of the SKBr3 and KMS11 culture superna-
tants.
Biochemical characterization of SEL1L variants
We next biochemically characterized the two new SEL1L
variants through isoelectrofocusing off-gel fractionation, coupled
to Western blot. The isoelectric points (pIs) of p38 and p28 ranged
between 5.25 and 5.50 (Figure S4A), resulting slightly more acidic
than the pI of SEL1LA, estimated at 5.8 (http://www.ncbi.nlm.nih.
gov/IEB/Research/Acembly). Such pI values are compatible with
the ultrastructural localization of N-terminal SEL1L labeling in late
endosomes/MVBs, which have pH values in the 5 to 6 range
[49,50]. Unlike SEL1LA [23], both p38 and p28 were resistant to
N-glycosidase F (PGNase F), which removes all types of N-linked
carbohydrates, and to endoglycosidase H (Endo H), which removes
high-mannose N-linked oligosaccharides (Figure S4B).
To isolate p38 and p28, SKBr3 lysates were immunoprecip-
itated with monoclonal anti-SEL1L N-terminus, fractionated by
SDS-PAGE and either immunoblotted (Figure 6A, left panel) or
Novel SEL1L Variants
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shown in Figure 6A, SEL1LA and p28 were immunoprecipitated
with different stoichiometric ratios (left panel, lane 3, arrows), but
p38, which yielded the most intensely recognized band by
immunoblotting, was not recovered in the immunoprecipitates
obtained using the same monoclonal antibody. The inability to
immunoprecipitate p38 even at small level suggests epitope
masking in the native protein, but not in the protein subjected to
Figure 2. Analysis of p38 and p28 secretion in SKBr3, KMS11 and MCF10A cells exposed to chemical and pharmacological
treatments. A. Western blot analysis of untreated and DTT-treated MCF10A cells: MCF10A cells were exposed to DTT (2 mM) for 3 hours and
successively maintained for 24 hrs in OPTIMEM. Secreted protein (50 mg) extracted from the culture medium by TCA precipitation, and aliquots of cell
lysates (50 mg) were resolved by SDS-PAGE (10%) and blotted with monoclonal anti-SEL1L and anti-vinculin antibodies. P38 was not detectable in the
culture medium, both in presence and in absence of DTT. In addition to p38, MCF10A cells showed a higher band, probably corresponding to an
immature precursor or post-translationally-modified product. The image is representative of two independent experiments. A1. RT-PCR analysis of
untreated and DTT-treated MCF10A cells: RNA was extracted from the samples described in panel A and analyzed by RT-PCR for the UPR response.
The histogram shows expression values normalized relative to housekeeping signals and expressed as fold modulation relative to the untreated
samples; densitometric analysis was performed by Scion imaging program. UPR activation upon DTT treatment is indicated by up-modulation of BIP
and CHOP and XBP-1 splicing, concomitantly SEL1LA is incremented (gray bar). The corresponding images are shown in Figure S2A. The data are the
averages of two different assays based on independent treatments, 6SD. B. Western blot analysis of untreated and DTT-treated SKBr3 cells: Secretion
of p38 and p28 was evaluated in untreated and DTT-treated SKBr3 cells. Cells exposed to DTT (2 mM) for 3 hrs or not exposed were maintained for
24 hrs in OPTIMEM. Secreted protein (50 mg) extracted from the culture medium by TCA precipitation, and aliquots of cell lysates (50 mg) were
resolved by SDS-PAGE (12%) and blotted with anti-SEL1L and anti-vinculin antibodies. ER stress/UPR strongly promoted secretion of p38 and, to a
lesser extent, p28 in the culture medium. The image is representative of five independent experiments. C. Western blot analysis of KMS11 cells
treated with DTT and MG132: KMS11 cells were exposed to DTT (2 mM) or MG132 (10 mM) for 3 hrs and successively maintained for 24 hrs in
OPTIMEM. Secreted protein (30 mg), extracted from the culture medium by TCA precipitation, and aliquots of cell lysates (50 mg) were resolved by
SDS-PAGE (10%) and blotted with anti-SEL1L and anti-vinculin antibodies. Both treatments markedly induced p38 secretion in the culture medium.
The image is representative of five independent experiments. C1. RT-PCR analysis of KMS11 cells treated with DTT and MG132: RNA was extracted
from the same samples described in panel C and analyzed by RT-PCR for the UPR response. The histogram shows expression values normalized
relative to housekeeping signals and expressed as fold modulation relative to untreated samples; densitometric analysis was determined by Scion
imaging program. UPR activation upon DTT treatment is indicated by the up-modulation of ATF6, BIP, and CHOP and by XBP-1 splicing (see Figure
S2C), concomitantly the expression of SEL1LA, HRD1 and GADD45b is incremented (gray bar). The corresponding images are shown in Figure S2C.
MG132 treatment did not trigger UPR activation, as indicated by the absence of ATF6 and BIP un-modulation and lack of XBP-1 splicing (see Figure
S2C), nevertheless, CHOP and GADD45b were markedly up-modulated and SEL1LA and HRD1 down-modulated (black bars). The data are averages of
four different assays based on independent treatments, 6SD. C2. SEL1LA protein expression in KMS11 cells treated with DTT and MG132: The
histogram shows SEL1LA protein expression values obtained from the samples described in panel C, normalized relative to housekeeping signals and
expressed as fold modulation relative to the untreated sample; densitometric analysis was performed using the Scion imaging program. MG132
determined SEL1LA protein accumulation up to 2 times relative to the control level (black bar). The data are the averages of four independent
experiments, 6SD.
doi:10.1371/journal.pone.0017206.g002
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additive post-translational modifications occurring only in the
p38 form; iii. nature of the p38 structure. Scaling-up the
immunoprecipitations allowed to detect by Coomassie staining
a 28 KDa protein band (Figure 6A, right panel, lane 4, arrow),
which was subjected to matrix-assisted laser desorption/ioniza-
tion–time-of-flight mass spectrometry (MALDI-TOF MS) analy-
sis. Surprisingly, MALDI-TOF MS revealed the presence of
peptides pertaining to TPD52 (Table 1), a secreted coiled-coil
motif-bearing cancer-associated protein implicated in endosomal
trafficking and in secretion via membrane-bound vesicles [51–
61]. TPD52 was readily detectable in SKBr3 cells (Figure S5A),
as expected based on the increased gene copy number reported in
this cell line [61]. Blast alignment between the coding sequences
of SEL1L and of three alternatively-spliced TPD52 isoforms
(accession numbers: P55327-1, P55327-2, P55327-3) did not
show similarities (data not shown), the monoclonal anti-SEL1L
N-terminus did not appear to recognize the myc/GFP-tagged
TPD52 isoform 1 (Figure S5B-C) and, in SKBr3 cells, siRNA
silencing of SEL1L did not affect TPD52 protein level (Figure
S5D). ER stress/UPR slightly promoted the release of TPD52 in
the SKBr3 culture medium (Figure S5E).
To investigate whether SEL1LA and/or p28 physically interact-
ed with TPD52, SKBr3 lysates were immunoprecipitated with
either anti-SEL1L N-terminus or anti-TPD52 antibodies and
conversely analyzed by Western blot using anti-TPD52 or anti-
SEL1L (Figure 6B). TPD52 was immunoprecipitated using
monoclonal anti-SEL1L (left panel, lane 3, arrow); reciprocally, in
spite of the low immunoprecipitation efficiency, p28, but not
SEL1LA, was recovered using anti-TPD52 (right panel, lane 3,
arrows). This suggests that in SKBr3 cells p28 and TPD52 interact,
with a stoichiometric imbalance that might reflect differences in
expression level and/or immunoprecipitation efficiency.
Overall, these results indicate that the pIs of p38 and p28 are
compatible with their presumed localization in endosomes/MVBs,
that both are underglycosylated, and that p28 interacts with the
cancer-associated protein TPD52, implicated in endosomal
trafficking and secretion via vesicles [51–61].
Figure 3. Localizations of SEL1L in untreated SKBr3 cells. Cryoimmunogold electron microscopy of untreated SKBr3 cells labeled with 10 nm
gold for N-terminal SEL1L (panels A, B) shows intense staining of vesicles (arrows) dispersed in the peripheral cytoplasm and sometimes associated
with multivesicular bodies and endosomes. Immunofluorescence reveals that SEL1L (green) extensively colocalizes (yellow) with the endoplasmic
reticulum marker calreticulin and, in a few dots, with the Golgi marker giantin (red), with the exception of discrete cytoplasmic foci (panels D–F,
squares) and of the peripheral cytoplasm (panels G–I, arrows). Bars: 0.1 mm; E: endosomes; er: endoplasmic reticulum; MVB: multivesicular body; PM:
plasma membrane.
doi:10.1371/journal.pone.0017206.g003
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17206Figure 4. Localizations of SEL1L in DTT-treated SKBr3 cells. After DTT treatment for 3 hrs, gold particles for N-terminal SEL1L (10 nm) are
found by cryoimmunogold electron microscopy along the microvilli (panel A) and on membrane-bound vesicles in the extracellular space (panels A,
A1) or emerging from the plasma membrane (panels C, F). Similarly, labeling for the tetraspan protein CD63 is detected in multivesicular bodies and
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We report here two new anchorless endogenous SEL1L variants,
p38 and p28, identified in lysates of different cell lines, including
KMS11 (multiple myeloma), 293FT (embryonic kidney), MCF7,
SKBr3 (breast cancer) and MCF10A (non-tumorigenic breast). In
addition to the signal of the canonical ER-resident SEL1LA protein,
we found distinct additive bands at approximately 38 KDa (p38)
and 28 KDa (p28). While p28 was detectable only in the poorly
differentiated breast cancer line SKBr3, p38 was expressed in all the
cell lines tested, at levels higher than SEL1LA and with stronger
signals in cancer cells. In this regard, recent studies of SEL1L
expression in human colorectal tumors revealed higher p38 levels in
adenomas compared to matched normal colonic mucosa, suggesting
an association between upregulation of p38 and in vivo colonic
tumorigenesis (Ashktorab et al., unpublished results).
Recognition by antibodies to the SEL1LA N-terminus, but not
to the C-terminus, and RNA interference assays indicate that p38
and p28 are low molecular mass N-terminal SEL1L forms, that
could originate either from splicing events at the 59 end of the
SEL1L pre-mRNA transcript, as the recently reported SEL1LB
and –C isoforms, cloned from RNA extracted from normal
peripheral blood lymphocytes [26], or, more likely, from
proteolytic cleavage of the ER-resident SEL1LA. In this regard
it is relevant that bioinformatic analysis predicts several cleavage
sites in the SEL1LA protein sequence (peptide cutter program,
http://expasy.org/tools/peptidecutter). The hypothesis that p38
could originate from SEL1LA cleavage would be consistent with
the evidence that DTT treatment upregulates SEL1LA mRNA, but
not SEL1LA protein level, which could suggest either that DTT,
by altering terminal folding, compromises SEL1LA stability, or
that most of SEL1LA undergoes cleavage to p38, that is then
secreted. In this case the band at about 55 KDa evidenced in
SKBr3 cells using antibody to the SEL1L C-terminus could
represent the carboxy-terminal fragment obtained after cleavage
of p38. Furthermore, we recently observed that miR183 negatively
Figure 5. Localizations of SEL1L in MG132-treated KMS11 cells. Cryoimmunogold electron microscopy of MG132-treated cells labeled with
15 nm gold for SEL1L N-terminus shows SEL1L localized mainly in internal vesicles of multivesicular bodies (arrows); with additional labeling in the
endoplasmic reticulum, Golgi complex and intracellular vesicles (panels A, C, arrows). In panel B a small SEL1L-labeled multivesicular body (arrow) lies
in direct apposition to the plasma membrane. Exosomal-like vesicles, that seem to originate from fusion of this multivesicular body with the plasma
membrane, bud into the extracellular space (arrowhead), suggesting that SEL1L is secreted via exosomes derived from the multivesicular body. Bars:
0.1 mm; er: endoplasmic reticulum; G: Golgi apparatus; MVB: multivesicular body; PM: plasma membrane.
doi:10.1371/journal.pone.0017206.g005
in vesicles at the cell surface (panels B, D, G, I). By double immunolabeling (panels E, H), N-terminal SEL1L (5–10 nm gold, arrowheads) localizes in
CD63-positive (15 nm gold, arrows) exosomes, while C-terminal SEL1L (panel J, arrowhead) is confined in the endoplasmic reticulum. Bars: 0.1 mm; E:
er: endoplasmic reticulum; Ly: lysosomes; MVB: multivesicular body; PM: plasma membrane.
doi:10.1371/journal.pone.0017206.g004
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that at least p38 results from a post-translational modification of
the SEL1LA product (Biunno, unpublished results). Thus, while
SEL1LB and –C are generated from alternatively-spliced mRNAs
expressed at low levels and up-modulated in cancer cells (Figure
S6) and under ER stress [26], the two new soluble SEL1L forms,
abundantly expressed in cancer cells, could likely originate from
proteolytic cleavage of SEL1LA.
As SEL1LB and -C, p38 and p28 lack the C-terminal SEL1LA
membrane-spanning region, but are predicted to retain several sel1-
Figure 6. SEL1L and TPD52 immunoprecipitations assays. A. SEL1LA and p28 immunoprecipitation analysis: Left panel: SKBr3 cell lysates
(1.4 mg) were immunoprecipitated with monoclonal anti-SEL1L antibody (lane 3), resolved by SDS-PAGE (10%) and probed with monoclonal anti-
SEL1L antibody. Lysate aliquots (50 mg, lane 1) were loaded to verify protein expression levels and immunoprecipitation efficiency. Arrows indicate
the immunoprecipitated bands, asterisks (*) correspond to heavy and light chains. Absence of signal in controls (lanes 4 and 5) confirms the
specificity of the immunoprecipitated bands. Right panel: SKBr3 cell lysates (7.0 mg) were immunoprecipitated with monoclonal anti-SEL1L antibody
(lane 4), resolved by SDS-PAGE (10%) and stained with Coomassie brilliant blue. Asterisks (*) correspond to heavy and light chains. The arrow
indicates the immunoprecipitated band analyzed by mass spectrometry. Absence of signal in controls (lanes 1 and 3) confirms the specificity of the
immunoprecipitated band. B. Analysis of the interaction between SEL1L variants and TPD52: Left panel: SKBr3 cell lysates (1.4 mg) were
immunoprecipitated with monoclonal anti-SEL1L antibody (lane 3), resolved by SDS-PAGE (10%) and probed with polyclonal anti-TPD52 antibody.
Lysate aliquots (40 mg, lane 4) were loaded to verify protein expression levels and immunoprecipitation efficiency. Lane 5 corresponds to unbound
aliquots of the samples loaded in lane 4 (40 mg). The arrow indicates the immunoprecipitated band. Absence of signal in controls (lanes 1 and 2)
confirms immunoprecipitation specificity. Right panel: SKBr3 lysates (1.4 mg) were immunoprecipitated with polyclonal anti-TPD52 antibody (lane 3),
resolved by SDS-PAGE (10%) and probed with monoclonal anti-SEL1L antibody. Lysate aliquots (40 mg, lane 4) were loaded to verify protein
expression levels and immunoprecipitation efficiency. Lane 5 corresponds to unbound aliquots of the samples loaded in lane 3 (40 mg). The
membrane was successively re-probed with anti-TPD52 antibody. Arrows indicate the immunoprecipitated bands. Absence of signal in controls (lanes
1 and 2) confirms immunoprecipitation specificity.
doi:10.1371/journal.pone.0017206.g006
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interaction modules [26,62–64]. Unlike SEL1LA [23], both p38
and p28 are PGNase F and Endo H resistant, which may reflect the
lack of the N-linked glycosylation sites at the SEL1LA C-terminus
[65,66], while the N-linked glycan identified in the SEL1LA N-
terminus [67] could be proximal to or beyond the splicing or
cleavage sites. The lack of asparagine-N-linked high-mannose-type
carbohydrate chains implies major differences in the folding,
oligomerization, sorting, and transport of p38 and p28 relative to
SEL1LA [68]. The modest depletion of the two new forms,
especially p38, after RNA interference or blockage of protein
synthesis, points to their higher stability compared to SEL1LA.
Most interestingly, p38 is constitutively secreted in the culture
media of the SKBr3 and KMS11 cancer cell lines, and secretion is
strongly augmented by ER stress or proteasomal blockage. The
p28 form is detectable in the SKBr3 culture medium only after ER
stress. Importantly, no SEL1L immunoreactive bands are found in
the MCF10A culture medium under normal and ER-stressed
conditions, suggesting that, at least in cells of breast epithelial
origin, secretion of the two soluble SEL1L forms is associated with
the tumorigenic phenotype.
Overall, the structural and functional properties of endogenous
p38 and p28 resemble those of the previously cloned exogenous
SEL1LC and -B in isoelectric point, high stability and localization
in endosomes/MVBs and secretory vesicles [26]. As SEL1LB and
-C, also p38 and p28 are predicted to be structurally related to
secreted bacterial virulence factors involved in pathogen-host
interactions, such as the Legionella pneumophila LpnE, EnhC and
LidL proteins and the Helicobacter pylori cysteine-rich protein A
(HcpA) [26,63]. LpnE is implicated in the ability of L. pneumophila
to establish infection and/or manipulate host cell trafficking
events, and its sel-1 like repeats, that interact with proteins
containing Ig-like domains, are necessary for host cell invasion
[69]. HcpA is a b-lactamase with hydrolytic activity, implicated in
drug resistance and proinflammatory/immune responses [70–72].
Morphological analyses indicate that in SKBr3 and KMS11
cells N-terminal SEL1L immunolabeling is detectable not only in
association with the ER, but also in endosomes/MVBs, along the
PM profiles and within peripheral cytoplasmic or extracellular
vesicles. These diverse subcellular localizations were observed
using two distinct antibodies to the SEL1L N-terminus, while an
antibody to the SEL1L C-terminus, unique to the ER-resident
SEL1LA, confirmed only the immunolabeling of the ER.
However, the N-terminal SEL1L antibody cannot discriminate
between p38 and p28, and the distribution of the N-terminal
SEL1L immunoreactivity in the different subcellular compart-
ments was similar in cell lines that express both p38 and p28, such
as SKBr3, or only p38, such as KMS11. By IEM, the N-terminal
SEL1L labeling in the vesicles shed by SKBr3 and KMS11 cells
appears to increase after induction of ER stress, in agreement with
the SDS-PAGE and immunoblot analysis of the culture superna-
tants. Furthermore, the co-immunoprecipitation data obtained in
SKBr3 cells suggest a functional parallelism between p28 and the
TPD52 family proteins, cancer markers that localize to endo-
somes/MVBs and act as regulators of membrane trafficking in
exocytic pathways [51–61]. MVBs are endosome-derived multi-
vesicular organelles containing hydrolases, which may evolve into
lysosomes or into secretory organelles [73,74]. The localization of
the N-terminal SEL1L immunolabeling in endosomes/MVBs is
consistent with the slightly acid pIs of p38 and p28 [49,50]. In this
regard, it is known that ER proteins that escape ERAD, as well as
ERAD components, can be targeted to the endosomal pathway for
lysosomal or basal autophagic degradation [74–76]. Alternatively,
endosomes/MVBs can be involved in exocytosis, which may
contribute to relieve ER stress through the expulsion of damaged
proteins and membrane constituents [77–79]. The extracellularly-
released vesicles containing N-terminal SEL1L products appear to
be heterogeneous in origin, deriving from vesicles segregated
within MVBs and discharged upon fusion with the plasma
membrane (exosomes), and from small plasma membrane
protrusions shed after fission of the stalk (shedding vesicles) [78–
80]. Notably, in agreement with our data, a recent report includes
SEL1L peptides among the proteins identified by mass spectrom-
etry in purified Rab27b-secretory vesicles of MCF7 breast cancer
cells [81]. Interestingly, Rab27b, a GTPase implicated in PM
delivery and fusion of different secretory vesicle types, is reported
to be present in CD63-containing multivesicular elements located
adjacent to the PM and in exosomes [81,82].
Vesicles participate in plasma membrane traffic and in
intercellular communication, enabling the horizontal transfer of
membrane and/or cargo molecules, including proteins and
mRNAs, from cell to cell or to the extracellular compartment,
where they can dissolve, releasing their contents. In this regard
shed vesicles provide platforms for integrated multisignaling,
required for rapid phenotype adjustments in cell populations [80].
Being extracellularly released, p38 and p28 could be found in
abnormal amounts in biological fluids, and could be potentially
developed as tumor markers. In this regard, it is intriguing that
bayesian network modelling of microarray and mass spectrometry
data identified an N-terminal SEL1LA sequence as a putative
serum biomarker of prostate cancer [83].
It could be speculated that p38 and p28, which seem to be
secreted only in tumorigenic cells, might be involved in hydrolytic
and proinflammatory processes associated with cancer-related
autocrine/paracrine signalling induced by ER stress. In this
respect, signaling via tumor-released vesicles is implicated in
processes that facilitate metastasis, such as extracellular matrix
remodelling, angiogenesis and migration [80]. Thus, p28 and p38
could represent new tumor markers and provide potential targets
for cancer therapy.
Supporting Information
Figure S1 P38 and p28 are not identified by antibody
against the SEL1L C-terminus and are detected in cancer
Table 1. TPD52 identification by MALDI-TOF MS analysis.
Band IPI
Acc.No.
Swissprot Entry name Protein name Theoretical pI/Mr Mowse Score Meas Pept Match Pep. Seq. Cov
1 IPI00619958 P55327 Human TPD52 Tumor protein D52 4.79/24327 177 76 18 82%
IPI: International Protein Index; Acc. No.: Accession number; Seq. Cov.: sequence coverage; pI: isoelectric point; Mr: relative molecular mass; MOWSE: MOlecular Weight
SEarch, probability based score used by the Mascot software which revealed higher probability with TPD52 isoform 1; Meas. Pep.: measured peptides; Matc. Pep.:
matching peptides.
doi:10.1371/journal.pone.0017206.t001
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terminus. A. P38 and p28 are not recognized by polyclonal
antibody against the SEL1L C-terminus: Lysates (50 mg) from
293FT (embryo kidney) and SKBr3 (breast cancer) cells were
resolved by SDS-PAGE (10%) and probed with polyclonal anti-
SEL1L C-terminus. Vinculin was used as a loading control. The
polyclonal C-terminal SEL1L antibody recognized the ER-resident
SEL1LA protein (95 KDa), but not the p38 and p28 forms. The
blot is representative of three independent experiments. B. p38,
detected with monoclonal antibody against the SEL1L N-terminus,
is more evident in cancer cells of various origins relative to a normal
human fetal brain cell line: Lysates (50 mg) from Namalwa
(lymphoma), MDAMB453 (breast cancer), HeLa (cervical cancer),
G144, G166 and G179 (glioblastoma) and CB660 (human fetal
brain) cells were resolved by SDS-PAGE (10%) and probed with
monoclonalanti-SEL1LN-terminus.Vinculinwasusedasa loading
control. P38 was expressed at much higher levels in the tested
cancer cell lines relative to CB660, while p28 was undetectable. A
higher band of approximately 60 KDa may represent an additional
SEL1L-related form expressed in glioblastoma cell lines.
(TIF)
Figure S2 UPR studies in MCF10A and SKBr3 cells
treated with DTT and in KMS11 cells treated with DTT
and MG132. A. RT-PCR analysis of DTT-treated MCF10A
cells: UPR activation was analyzed by RT-PCR in the samples
described in Figure 2A1. UPR activation was confirmed by XBP-1
splicing and up-modulation of BIP and CHOP. HPRT serves as
internal control. The image is representative of two different assays
based on independent treatments. B. RT-PCR analysis of DTT-
treated SKBr3 cells: RNA was extracted from the samples
described in Figure 2B and analyzed by RT-PCR for the UPR.
UPR activation was confirmed by XBP-1 splicing and CHOP up-
modulation, concomitantly with increase of SEL1LA. HPRT serves
as internal control. The image is representative of five different
assays based on independent treatments. C. RT-PCR analysis of
DTT- and MG132-treated KMS11 cells: UPR activation was
assessed by RT-PCR on KMS11 cells treated with DTT or with
MG132. UPR activation upon DTT treatment was confirmed by
XBP-1 splicing and CHOP, BIP and ATF6 up-modulation;
concomitantly SEL1LA also increased. MG132 treatment for
3 hrs resulted in an increase of CHOP and GADD45b, but there
was no evidence of XBP-1 splicing and BIP and ATF6 modulation.
Concomitantly, SEL1LA and HRD1 decreased. After 22 hours of
MG132 treatment, BIP, CHOP and GADD45b increased. HPRT
serves as internal control. The image is representative of five
different assays based on independent treatments.
(TIF)
Figure S3 Localizations of SEL1L in DTT-treated
SKBr3 cells and of myc-tagged exogenous SEL1LB in
transfected 293FT cells. Immunofluorescence shows that in
DTT-treated SKBr3 cells N-terminal SEL1L (green) intensely
labels peripheral areas negative for the endoplasmic reticulum
marker calreticulin and for the Golgi marker giantin (panels A–
F). Cryoimmunogold electron microscopy of DTT-treated SKBr3
cells shows N-terminal SEL1L labeling in multivesicular bodies
(panel G, arrowhead), on endoplasmic reticulum profiles,
identified by calreticulin (panel G arrows), and in vesicles
released from the plasma membrane after fission of the stalk
(panels H-I, arrows point to stalks). Similarly, in SEL1L-Bmyc-
transfected 293FT cells, exogenous myc-tagged SEL1LB labeling
was detected along plasma membranes and in vesicles emerging
from plasma membrane (panels J–K, arrows). Bars: 0.1 mm; er:
endoplasmic reticulum; MVB: multivesicular body; PM: plasma
membrane.
(TIF)
Figure S4 Biochemical characterization of SEL1L vari-
ants. A. Off-gel electrophoresis and Western blot analysis: Off-gel
electrophoresis coupled with Western blot analysis was used to
analyze the pIs of p38 and p28. The proteins extracted from the
medium of DTT-treated SKBr3 cells were fractionated according
to their pI using an Off-gel 3100 fractionator (Agilent Technol-
ogies) and aliquots of these fractions were analyzed by Western
blot with monoclonal anti-SEL1L antibody. Both p38 and p28
(arrows) were detected in the six
th fraction, corresponding to the pI
range of 5.25–5.50. B. N-glycosidase F (PGNase F) and
endoglycosidase H (Endo H) digestions: SKBr3 cell lysates
(80 mg) were incubated with endo H (H) and PGNase F (F),
fractionated on SDS-PAGE (10%) and blotted with monoclonal
anti-SEL1L antibody. Both p38 and p28 are PNGase F and endo
(H) resistant. Note the mobility shifts of treated SEL1LA (see
arrow).
(TIF)
Figure S5 TPD52 analysis. A. TPD52 protein expression:
Lysates (50 mg) from different cell lines, including 293FT
(embryonic kidney), KMS11 (multiple myeloma), MCF7,
MDAMB453, and SKBr3 (breast cancer) were resolved by SDS-
PAGE (10%) and probed with polyclonal anti-TPD52 antibody.
Vinculin was used as a loading control. SKBr3 cells over-expressed
TPD52. The blot is representative of three independent
experiments. B–C. SEL1L antibody does not recognize TPD52.
B: To exclude possible TPD52 protein recognition by anti-SEL1L
antibody, lysates (50 mg) obtained from 293FT cells transfected
with myc-tagged TPD52 isoform 1 or empty vector (mock) were
resolved by SDS-PAGE (10%) and probed with anti-myc, anti-
SEL1L and anti-TPD52 antibodies recognizing TPD52 isoforms 1
and 2. Exogenous tagged TPD52 isoform 1 acquired a molecular
weight similar to that of endogenous p38 (arrows for exogenous
TPD52 isoform 1 and asterisks for endogenous p38), interfering
with the evaluation of SEL1L antibody cross-reactivity. However,
no increase of reactivity was observed in cells transfected with myc-
TPD52 isoform 1. Both myc and TPD52 antibodies selectively
detected the exogenous protein (see arrows), confirming correct
translation. C: Lysates (50 mg) from 293FT cells transfected with
GFP-tagged TPD52 isoform 1 or empty vector (mock) were
resolved by SDS-PAGE (10%) and probed with anti-GFP, anti-
SEL1L and anti-TPD52 antibodies. Exogenous tagged TPD52
isoform 1 acquired a molecular weight of 58 KDa, well
distinguishable from the endogenous SEL1L bands (see arrows
for exogenous TPD52 isoform 1 and asterisks for endogenous p38
and SEL1LA). No or barely detectable reactivity with SEL1L
antibody was observed in cells transfected with TPD52 isoform 1.
Both GFP and TPD52 antibodies selectively detected the
exogenous protein, confirming correct translation. D: TPD52
protein levels are unaffected by SEL1L small interfering RNA
(siRNA): Lysates obtained from the same samples described in
Figure 1 C were resolved by SDS-PAGE (12%) and blotted with
anti-TPD52 antibody. While SEL1LA, p28 and p38 decreased
close to 55%, 30% and 16% respectively, compared to cells
treated with scrambled siRNA (see Figure 1C), TPD52 levels did
not change. Vinculin was used as a loading control. E: TPD52
secretion is enhanced in SKBr3 cells exposed to DTT: Lysates and
secreted proteins obtained from the samples described in Figure 2A
were resolved by SDS-PAGE (12%) and blotted with anti-TPD52
and anti-vinculin antibodies. ER stress/UPR slightly promoted
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representative of two independent experiments.
(TIF)
Figure S6 SEL1LB and -C transcripts are up-modulated
in cancer cell lines. RNAs extracted from KMS11, MCF10A
and SKBr3 cells were analyzed by RT-PCR using primers specific
for SEL1LB and -C. Signals shown here were obtained with 30
cycles for both isoforms. HPRT was used as a loading control. The
SEL1LB and –C transcripts were up-modulated in the tested tumor
cell lines relative to the non-tumorigenic MCF10A line. The image
is representative of three different assays based on independent
experiments.
(TIF)
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